ABSTRACT
Both diabetic and prediabetic patients have abnormal vascular reactivity and should be considered to have occult cardiovascular disease. Angiotensin-converting-enzyme (ACE) inhibitors are particularly beneficial in diabetes because they reduce the incidence of both cardiovascular events and diabetes-related complications. In prediabetic patients, ACE inhibitors also reduce the risk of a new diagnosis of type 2 diabetes. Managing hypertension is even more beneficial for diabetic patients than for nondiabetic patients. To further reduce the risk of heart disease in patients with diabetes or prediabetes, dyslipidemia should also be treated aggressively.
Footnotes
↵* The author has indicated that she has received grant or research support from the Bristol-Myers Squibb and Parke-Davis corporations, and serves as a consultant and on the speakers’ bureau for Merck and Co. Her lecture was supported by a grant from Parke-Davis.
- Copyright © 2000 The Cleveland Clinic Foundation. All Rights Reserved.